Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.
National Institute of Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
BMJ Open. 2021 Oct 7;11(10):e045802. doi: 10.1136/bmjopen-2020-045802.
A Low Glycaemic Index (LGI) diet is a proposed lifestyle intervention in non-alcoholic fatty liver diseases (NAFLD) which is designed to reduce circulating blood glucose levels, hepatic glucose influx, insulin resistance and de novo lipogenesis. A significant reduction in liver fat content through following a 1-week LGI diet has been reported in healthy volunteers. Changes in dietary fat and carbohydrates have also been shown to alter gut microbiota composition and lead to hepatic steatosis through the gut-liver axis. There are no available trials examining the effects of an LGI diet on liver fat accumulation in patients with NAFLD; nor has the impact of consuming an LGI diet on gut microbiota composition been studied in this population. The aim of this trial is to investigate the effects of LGI diet consumption on liver fat content and its effects on gut microbiota composition in participants with NAFLD compared with a High Glycaemic Index (HGI) control diet.
A 2×2 cross-over randomised mechanistic dietary trial will allocate 16 participants with NAFLD to a 2-week either HGI or LGI diet followed by a 4-week wash-out period and then the LGI or HGI diet, alternative to that followed in the first 2 weeks. Baseline and postintervention (four visits) outcome measures will be collected to assess liver fat content (using MRI/S and controlled attenuation parameter-FibroScan), gut microbiota composition (using 16S RNA analysis) and blood biomarkers including glycaemic, insulinaemic, liver, lipid and haematological profiles, gut hormones levels and short-chain fatty acids.
Study protocol has been approved by the ethics committees of The University of Nottingham and East Midlands Nottingham-2 Research Ethics Committee (REC reference 19/EM/0291). Data from this trial will be used as part of a Philosophy Doctorate thesis. Publications will be in peer-reviewed journals.
NCT04415632.
低升糖指数(LGI)饮食是一种针对非酒精性脂肪性肝病(NAFLD)的生活方式干预措施,旨在降低循环血糖水平、肝葡萄糖摄入、胰岛素抵抗和从头合成脂肪。在健康志愿者中,通过遵循为期一周的 LGI 饮食,已经报道了肝脂肪含量的显著减少。饮食中脂肪和碳水化合物的变化也已被证明可以改变肠道微生物群落组成,并通过肠道-肝脏轴导致肝脂肪变性。目前尚无研究检查 LGI 饮食对 NAFLD 患者肝脂肪堆积的影响;也没有研究过在该人群中,LGI 饮食对肠道微生物群落组成的影响。本试验的目的是研究 LGI 饮食对 NAFLD 患者肝脂肪含量的影响及其对肠道微生物群落组成的影响,与高升糖指数(HGI)对照饮食进行比较。
将 16 名 NAFLD 患者随机分为 2 周 HGI 或 LGI 饮食组,然后进行 4 周洗脱期,然后交替进行 LGI 或 HGI 饮食,与前 2 周的饮食不同。将收集基线和干预后(4 次访视)的结果测量值,以评估肝脂肪含量(使用 MRI/S 和受控衰减参数-FibroScan)、肠道微生物群落组成(使用 16S RNA 分析)以及血糖、胰岛素、肝、脂质和血液生物标志物的变化,包括血液学概况、肠道激素水平和短链脂肪酸。
研究方案已获得诺丁汉大学和东米德兰兹诺丁汉 2 研究伦理委员会的伦理委员会批准(REC 参考号 19/EM/0291)。本试验的数据将作为哲学博士论文的一部分使用。出版物将发表在同行评议的期刊上。
NCT04415632。